Fructose‐Coated Ångstrom Silver Particles Suppress Gastric Cancer Growth by Activating Gasdermin D‐Mediated Pyroptosis
You-You Li,Kun Xia,Yi-Wei Liu,Yi-Juan Tan,Hong-Ming Li,Yi-Yi Wang,Shi-Kai Feng,Ling Jin,Teng-Fei Wan,Jia Cao,Chun-Yuan Chen,Zheng-Zhao Liu,Xiong-Ke Hu,Ben Wu,Yang Wang,Ze-Hui He,Hao Yin,Wei-Yi Situ,Lu-Yue Qi,Zhen-Xing Wang,Hui Xie
DOI: https://doi.org/10.1002/adtp.202200100
IF: 5.003
2022-01-01
Advanced Therapeutics
Abstract:Gastric cancer (GC) remains an important cancer worldwide, ranking fifth for incidence and fourth for mortality globally. Surgery combined with chemotherapy is recognized as a curative regimen for GC. However, much safer and more effective methods should be developed to improve the survival rate. Formerly, a pure physical method is presented to prepare Angstrom-scale silver particles (AgAPs) and anticancer effects of fructose-coated AgAPs (F-AgAPs) are found. In this research, the efficacy and alternative pyroptosis induction of F-AgAPs in the treatment of GC are investigated and compared with those of cisplatin in subcutaneous GC tumor-bearing nude mice. F-AgAPs inhibit GC cell growth, promote lactate dehydrogenase (LDH) release, and induce cell pyroptosis in vitro. The caspase-1 selective inhibitor belnacasan (VX-765) and the pyroptotic pore formation inhibitor necrosulfonamide (NSA) partially reverse F-AgAP-induced pyroptosis in GC cells. In vivo, F-AgAPs significantly upregulate inflammasome formation, caspase-1 expression, and gasdermin D (GSDMD) cleavage, thus inducing pyroptosis. Furthermore, intravenous and oral administrations of F-AgAPs do not induce any obvious toxicities in healthy tissues. This study indicates that GSDMD-dependent pyroptosis is a novel mechanism by which F-AgAPs protect against GC in vitro and in vivo, which may provide a new therapeutic strategy for anti-GC treatment.